Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $1.4 billion.

  • Cytokinetics' Liabilities and Shareholders Equity rose 0.03% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 16.02%. This contributed to the annual value of $1.4 billion for FY2024, which is 70.04% up from last year.
  • Cytokinetics' Liabilities and Shareholders Equity amounted to $1.4 billion in Q3 2025, which was up 17.21% from $1.2 billion recorded in Q2 2025.
  • Cytokinetics' Liabilities and Shareholders Equity's 5-year high stood at $1.5 billion during Q2 2024, with a 5-year trough of $564.3 million in Q2 2021.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.2 billion (2025), whereas its average is $1.1 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 142.72% in 2021, then tumbled by 31.17% in 2023.
  • Cytokinetics' Liabilities and Shareholders Equity (Quarterly) stood at $841.3 million in 2021, then rose by 20.62% to $1.0 billion in 2022, then decreased by 18.77% to $824.3 million in 2023, then soared by 70.04% to $1.4 billion in 2024, then climbed by 0.03% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.